4.7 Review

Overcoming TGFβ-mediated immune evasion in cancer

期刊

NATURE REVIEWS CANCER
卷 22, 期 1, 页码 25-44

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41568-021-00413-6

关键词

-

类别

资金

  1. Radboudumc
  2. Dutch Research Council (NWO-ZonMw VIDI programme) [91719371]
  3. ERC [884623]
  4. World Wide Cancer Research grant [19_0005]
  5. la Caixa Foundation [HR18-00359]
  6. Spanish Association Against Cancer (AECC) [PROYE18046BATL]
  7. Government of Catalonia [AGAUR-SGR698]
  8. European Research Council (ERC) [884623] Funding Source: European Research Council (ERC)

向作者/读者索取更多资源

This review discusses the role of TGF beta in the tumour immune microenvironment and the importance of TGF beta inhibition in restoring cancer immunity. TGF beta controls multiple cell fate decisions during development and tissue homeostasis, and dysregulation of this pathway can lead to various diseases including cancer. The context-dependent functions of TGF beta in the tumour microenvironment play a crucial role in suppressing or promoting cancer.
This Review discusses the context-dependent functions of transforming growth factor-beta (TGF beta) with regard to the composition and behaviour of different cell populations in the tumour immune microenvironment, as well as emerging data that demonstrate that TGF beta inhibition can restore cancer immunity. Transforming growth factor-beta (TGF beta) signalling controls multiple cell fate decisions during development and tissue homeostasis; hence, dysregulation of this pathway can drive several diseases, including cancer. Here we discuss the influence that TGF beta exerts on the composition and behaviour of different cell populations present in the tumour immune microenvironment, and the context-dependent functions of this cytokine in suppressing or promoting cancer. During homeostasis, TGF beta controls inflammatory responses triggered by exposure to the outside milieu in barrier tissues. Lack of TGF beta exacerbates inflammation, leading to tissue damage and cellular transformation. In contrast, as tumours progress, they leverage TGF beta to drive an unrestrained wound-healing programme in cancer-associated fibroblasts, as well as to suppress the adaptive immune system and the innate immune system. In consonance with this key role in reprogramming the tumour microenvironment, emerging data demonstrate that TGF beta-inhibitory therapies can restore cancer immunity. Indeed, this approach can synergize with other immunotherapies - including immune checkpoint blockade - to unleash robust antitumour immune responses in preclinical cancer models. Despite initial challenges in clinical translation, these findings have sparked the development of multiple therapeutic strategies that inhibit the TGF beta pathway, many of which are currently in clinical evaluation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据